Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
03. Dezember 2024 16:01 ET
|
Tectonic Therapeutic
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of...
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
26. November 2024 16:01 ET
|
Tectonic Therapeutic
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of...
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
11. November 2024 05:00 ET
|
Tectonic Therapeutic
Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow...
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
07. November 2024 16:01 ET
|
Tectonic Therapeutic
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First subject dosed with TX000045 (“TX45”) in APEX...
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
22. Oktober 2024 16:01 ET
|
Tectonic Therapeutic
WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of...
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19. September 2024 16:01 ET
|
Tectonic Therapeutic
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at...
Tectonic Therapeutic to Participate in September Investor Conferences
20. August 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14. August 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
30. Juli 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
01. Februar 2019 07:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...